Jiangtao Ren

3.7k total citations · 3 hit papers
15 papers, 2.3k citations indexed

About

Jiangtao Ren is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Jiangtao Ren has authored 15 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 5 papers in Genetics. Recurrent topics in Jiangtao Ren's work include CRISPR and Genetic Engineering (12 papers), CAR-T cell therapy research (10 papers) and Pluripotent Stem Cells Research (5 papers). Jiangtao Ren is often cited by papers focused on CRISPR and Genetic Engineering (12 papers), CAR-T cell therapy research (10 papers) and Pluripotent Stem Cells Research (5 papers). Jiangtao Ren collaborates with scholars based in China, United States and United Kingdom. Jiangtao Ren's co-authors include Yangbing Zhao, Carl H. June, Shuguang Jiang, Xiaojun Liu, Chongyun Fang, Yanping Luo, Brian Keith, Biliang Hu, John Scholler and Regina M. Young and has published in prestigious journals such as Blood, Clinical Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Jiangtao Ren

15 papers receiving 2.2k citations

Hit Papers

Multiplex Genome Editing to Generate Universal CAR T Cell... 2016 2026 2019 2022 2016 2017 2021 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
    2016 738 citations Jiangtao Ren, Xiaojun Liu et al. Clinical Cancer Research profile →
  2. Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
    2017 400 citations Biliang Hu, Jiangtao Ren et al. Cell Reports profile →
  3. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    2021 202 citations Yongxian Hu, Yali Zhou et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiangtao Ren China 13 1.5k 1.4k 769 526 523 15 2.3k
Laurent Poirot France 22 2.0k 1.3× 1.4k 1.0× 1.1k 1.5× 718 1.4× 1.1k 2.1× 46 3.2k
Levi J. Rupp United States 8 1.5k 1.0× 970 0.7× 501 0.7× 635 1.2× 1.1k 2.0× 12 2.6k
Dimitrios L. Wagner Germany 13 1.2k 0.8× 904 0.6× 532 0.7× 311 0.6× 483 0.9× 26 1.8k
Helen Huls United States 31 2.9k 1.9× 1.4k 1.0× 1.3k 1.7× 852 1.6× 1.3k 2.4× 55 3.7k
Hiroki Torikai United States 17 957 0.6× 577 0.4× 452 0.6× 235 0.4× 634 1.2× 32 1.4k
Sjoukje J. C. van der Stegen United States 13 4.1k 2.7× 1.7k 1.2× 1.3k 1.7× 1.5k 2.8× 1.5k 3.0× 18 4.7k
Blythe Sather United States 19 733 0.5× 671 0.5× 442 0.6× 135 0.3× 1.1k 2.1× 29 2.0k
Harvey A. Greisman United States 14 889 0.6× 859 0.6× 385 0.5× 208 0.4× 444 0.8× 22 1.8k
Christopher C. Kloss United States 11 2.2k 1.5× 932 0.7× 679 0.9× 820 1.6× 925 1.8× 15 2.6k
Bian Hu China 17 389 0.3× 1.1k 0.8× 360 0.5× 81 0.2× 196 0.4× 30 1.5k

Countries citing papers authored by Jiangtao Ren

Since Specialization
Citations

This map shows the geographic impact of Jiangtao Ren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiangtao Ren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiangtao Ren more than expected).

Fields of papers citing papers by Jiangtao Ren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiangtao Ren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiangtao Ren. The network helps show where Jiangtao Ren may publish in the future.

Co-authorship network of co-authors of Jiangtao Ren

This figure shows the co-authorship network connecting the top 25 collaborators of Jiangtao Ren. A scholar is included among the top collaborators of Jiangtao Ren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiangtao Ren. Jiangtao Ren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Hu, Yongxian, Yali Zhou, Mingming Zhang, et al.. (2024). A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial. Blood. 144(Supplement 1). 921–921. 1 indexed citations
2.
Ren, Jiangtao, et al.. (2023). Apoptosis inhibition enhances induced pluripotent stem cell generation during T cell reprogramming. Biochemical and Biophysical Research Communications. 656. 30–37. 2 indexed citations
3.
Liu, Yuanyuan, Yanxin Zheng, Yue Huang, et al.. (2022). Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy. Frontiers in Oncology. 12. 1037934–1037934. 22 indexed citations
4.
Hu, Yongxian, Yali Zhou, Mingming Zhang, et al.. (2021). CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research. 27(10). 2764–2772. 202 indexed citations breakdown →
5.
Hu, Yongxian, Yali Zhou, Mingming Zhang, et al.. (2020). The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Blood. 136(Supplement 1). 52–52. 13 indexed citations
6.
Zhang, Xuhua, Linping Xu, Ruihua Fan, et al.. (2018). Genetic editing and interrogation with Cpf1 and caged truncated pre-tRNA-like crRNA in mammalian cells. Cell Discovery. 4(1). 36–36. 15 indexed citations
7.
Ren, Jiangtao, Xuhua Zhang, Xiaojun Liu, et al.. (2017). A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 8(10). 17002–17011. 315 indexed citations
8.
Ren, Jiangtao & Yangbing Zhao. (2017). Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein & Cell. 8(9). 634–643. 82 indexed citations
9.
Hu, Biliang, Jiangtao Ren, Yanping Luo, et al.. (2017). Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. Cell Reports. 20(13). 3025–3033. 400 indexed citations breakdown →
10.
Ren, Jiangtao, Xiaojun Liu, Chongyun Fang, et al.. (2016). Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clinical Cancer Research. 23(9). 2255–2266. 738 indexed citations breakdown →
11.
Ren, Jiangtao, Xiaojun Liu, Chongyun Fang, et al.. (2015). Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia. Blood. 126(23). 4280–4280. 12 indexed citations
12.
Lu, Pengfei, Ji‐Jun Chen, Lixiazi He, et al.. (2013). Generating Hypoimmunogenic Human Embryonic Stem Cells by the Disruption of Beta 2-Microglobulin. Stem Cell Reviews and Reports. 9(6). 806–813. 59 indexed citations
13.
Rao, Lingjun, Wenjie Tang, Youzhen Wei, et al.. (2012). Highly Efficient Derivation of Skeletal Myotubes from Human Embryonic Stem Cells. Stem Cell Reviews and Reports. 8(4). 1109–1119. 28 indexed citations
14.
Bao, Lei, Lixiazi He, Ji‐Jun Chen, et al.. (2011). Reprogramming of ovine adult fibroblasts to pluripotency via drug-inducible expression of defined factors. Cell Research. 21(4). 600–608. 93 indexed citations
15.
Wu, Zhao, Ji‐Jun Chen, Jiangtao Ren, et al.. (2009). Generation of Pig Induced Pluripotent Stem Cells with a Drug-Inducible System. Journal of Molecular Cell Biology. 1(1). 46–54. 291 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurent Poirot Breakdown of academic impact, for papers by Levi J. Rupp Breakdown of academic impact, for papers by Dimitrios L. Wagner Breakdown of academic impact, for papers by Helen Huls Breakdown of academic impact, for papers by Hiroki Torikai Breakdown of academic impact, for papers by Sjoukje J. C. van der Stegen Breakdown of academic impact, for papers by Blythe Sather Breakdown of academic impact, for papers by Harvey A. Greisman Breakdown of academic impact, for papers by Christopher C. Kloss Breakdown of academic impact, for papers by Bian Hu
Rankless by CCL
2026